Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 06, 2016 3:14 AM ET

Biotechnology

Company Overview of Envisia Therapeutics Inc.

Company Overview

Envisia Therapeutics Inc. is engaged in the discovery and development of ocular therapeutics for the critical needs in ophthalmology. The company offers ENV515, a prostaglandin analogue that uses a biodegradable PRINT particle formulation to provide sustained intraocular pressure reduction over months. It also provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic, chemical, or other barriers that limit existing ocular therapies; therapeutics based on biocompatible polymers for the delivery of medicines with extended-release kinetics; and topical therapies for treating ocular diseases. The company was founded in 2013 and is based in Morrisville, North ...

419 Davis Drive

Suite 100

Morrisville, NC 27560

United States

Founded in 2013

Phone:

919-973-1440

Fax:

919-973-1441

Key Executives for Envisia Therapeutics Inc.

Chief Executive Officer and Director
Age: 53
Co-Founder, President and Chief Scientific Officer
Age: 49
Executive Chairman
Chief Financial Officer
Chief Medical Officer
Compensation as of Fiscal Year 2015.

Envisia Therapeutics Inc. Key Developments

Envisia Therapeutics Dostes First Patient in Second Cohort of Novel Phase 2 Program Evaluating ENV515 in Patients with Glaucoma

Envisia Therapeutics announced that it has dosed its first patient in the second cohort of the phase 2 clinical program evaluating the company's lead product candidate, ENV515. ENV515 is an extended-release formulation of travoprost that could offer sustained reduction in intraocular pressure (IOP) for more than six months after a single dose. ENV515 is a fully biodegradable proprietary PRINT® nanoparticle formulation of a marketed prostaglandin analog that has the potential to lower IOP for more than 6 months from a single dose. ENV515 has the potential to address the issue of poor patient compliance that exists with daily eye drops and limit the progression of glaucoma that sometimes leads to vision loss. Envisia is also leveraging the Company's unique platform technology to develop products for other leading ocular diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), and ocular inflammation.

Envisia Therapeutics Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-12-2016 08:30 AM

Envisia Therapeutics Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-12-2016 08:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Benjamin R. Yerxa, Co-Founder, President and Chief Scientific Officer.

Envisia Therapeutics Appoints William E. Yelle as Executive Chairman of the Board of Directors

Envisia Therapeutics announced the appointment of William E. Yelle as executive chairman of the Board of Directors. Yelle succeeds Gary M. Phillips, M.D., who will continue to serve as a director. Envisia also announced the retirement of Board member, Seth A. Rudnick, M.D., adjunct Clinical Professor of Medicine at the University of North Carolina-Chapel Hill, and recently retired Partner at Canaan Partners. Yelle has over 25 years of experience in the life sciences industry, including positions in executive management, corporate and business development, strategic planning, portfolio management, commercial operations and R&D. Most recently, he served as Chief Executive Officer of Aldea Pharmaceuticals, where he built an executive team, completed a successful Series B financing and brought two programs into the clinic. Prior to Aldea, Yelle was Senior Vice President of Corporate Development for Sunovion Pharmaceuticals Inc.

Similar Private Companies By Industry

Company Name Region
Bio-Synthesis, Inc. United States
Glauconix, Inc. United States
MK Stem Cell Inc. United States
Advenchen Laboratories, LLC United States
Receptor Biology, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
October 1, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Envisia Therapeutics Inc., please visit www.envisiatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.